A retrospective cohort study investigated the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival ...

There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The significance of androgen receptor signaling pathway in mCRPC patients receiving olaparib monotherapy or combined treatment with abiraterone. Circulating tumor cell expression analysis from the ...

Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with olaparib within its marketing authorisation as maintenance treatment of advanced squamous non-small-cell lung ...

AstraZeneca has launched new lawsuits against four generic drug manufacturers in an ongoing patent battle over its cancer drug Lynparza (olaparib), approved to treat ovarian, pancreatic ...